Tenax Therapeutics (NASDAQ:TENX) Now Covered by Analysts at StockNews.com

Equities researchers at StockNews.com started coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a research report issued on Sunday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Stock Up 1.2 %

Shares of TENX stock opened at $3.01 on Friday. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20. The firm’s 50 day moving average price is $3.45 and its two-hundred day moving average price is $7.30.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, May 14th. The specialty pharmaceutical company reported ($3.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.40) by ($0.72). As a group, sell-side analysts expect that Tenax Therapeutics will post -7.96 earnings per share for the current fiscal year.

About Tenax Therapeutics

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.